
Thomas A Fleisher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1581784/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21. Journal of Allergy and Clinical Immunology, 2022, 149, 302-314.	2.9	4
2	Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies. Blood, 2021, 137, 349-363.	1.4	32
3	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. , 2021, 9, e002193.		27
4	T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. Journal of Experimental Medicine, 2021, 218, .	8.5	18
5	A Nonsense N –Terminus NFKB2 Mutation Leading to Haploinsufficiency in a Patient with a Predominantly Antibody Deficiency. Journal of Clinical Immunology, 2020, 40, 1093-1101.	3.8	7
6	⁹⁰ Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 249-261.	1.0	9
7	Lymphocyte reference intervals in the era of newborn screening. Journal of Allergy and Clinical Immunology, 2019, 144, 1516-1517.	2.9	2
8	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
9	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clinical Cancer Research, 2019, 25, 4945-4954.	7.0	82
10	Flow cytometry: Surface markers and beyond. Journal of Allergy and Clinical Immunology, 2019, 143, 528-537.	2.9	44
11	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood, 2018, 132, 1737-1749.	1.4	128
12	Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. Journal of Clinical Investigation, 2018, 128, 3071-3087.	8.2	133
13	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT, Biology of Blood and Marrow Transplantation, 2017, 23, 379-387.	2.0	49
14	Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. Journal of Allergy and Clinical Immunology, 2017, 139, 1629-1640.e2.	2.9	147
15	The microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2017, 139, 1099-1110.	2.9	264
16	Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 2017, 139, 715-723.	2.9	54
17	Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biology of Blood and Marrow Transplantation. 2017. 23. 1229-1240.	2.0	44
18	Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: The NIH experience. Journal of Allergy and Clinical Immunology, 2017, 140, 622-625.	2.9	35

THOMAS A FLEISHER

#	Article	IF	CITATIONS
19	Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype. Blood, 2017, 130, 1553-1564.	1.4	82
20	Diagnostic dilemma: ALPS versus Evans syndrome. Clinical Immunology, 2017, 183, 247-248.	3.2	4
21	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	5.0	219
22	A Novel Mutation in IKBKG/NEMO Leads to Ectodermal Dysplasia with Severe Immunodeficiency (EDA-ID). Journal of Clinical Immunology, 2016, 36, 541-543.	3.8	6
23	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2016, 22, 3182-3191.	7.0	109
24	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood, 2015, 125, 784-792.	1.4	200
25	Hypomorphic interleukin-7 receptor α-chain mutations and T-cell deficiency: a delay in diagnosis. Annals of Allergy, Asthma and Immunology, 2015, 115, 1-3.	1.0	6
26	⁹⁰ Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13045-13050.	7.1	44
27	Targeted NGS: A Cost-Effective Approach to Molecular Diagnosis of PIDs. Frontiers in Immunology, 2014, 5, 531.	4.8	105
28	BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies. Journal of Allergy and Clinical Immunology, 2014, 133, 1134-1141.	2.9	212
29	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nature Immunology, 2014, 15, 88-97.	14.5	575
30	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. Journal of Allergy and Clinical Immunology, 2014, 133, 1092-1098.	2.9	301
31	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	2.9	65
32	An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nature Genetics, 2014, 46, 1140-1146.	21.4	585
33	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> . Science, 2014, 345, 1623-1627.	12.6	745
34	The BH3 Mimetic, Small Molecule, ABT-737, Was Effective As Lympholytic Therapy in the MRL/lprâ^'/â^' Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). Blood, 2011, 118, 695-695.	1.4	0
35	Rituximab Is Associated with Prolonged Immunoglobulin Deficiency In Newly Diagnosed Patients with Aggressive B-Cell Lymphoma Receiving Immunochemotherapy. Blood, 2010, 116, 2881-2881.	1.4	1
36	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Blood, 2008, 112, 2010-2010.	1.4	1

THOMAS A FLEISHER

#	Article	IF	CITATIONS
37	Evaluation of Suspected Immunodeficiency. Advances in Experimental Medicine and Biology, 2007, 601, 291-300.	1.6	5
38	Back to Basics: Primary Immune Deficiencies: Windows into the Immune System. Pediatrics in Review, 2006, 27, 363-372.	0.4	13
39	Autoimmune lymphoproliferative syndrome. Israel Medical Association Journal, 2005, 7, 758-61.	0.1	8
40	Functional and molecular evaluation of lymphocytes. Journal of Allergy and Clinical Immunology, 2004, 114, 227-234.	2.9	42
41	Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood, 2001, 98, 2466-2473.	1.4	129
42	The Autoimmune Lymphoproliferative Syndrome. Clinical Reviews in Allergy and Immunology, 2001, 20, 109-120.	6.5	14
43	Reduction in HTLVâ€I proviral load and spontaneous lymphoproliferation in HTLVâ€I–associated myelopathy/tropical spastic paraparesis patients treated with humanized antiâ€tac. Annals of Neurology, 1998, 44, 942-947.	5.3	70
44	Intestinal lymphangiectasia, a disease characterized by selective loss of naive CD45RA+ lymphocytes into the gastrointestinal tract. European Journal of Immunology, 1998, 28, 4275-4285.	2.9	59
45	Development of Antibodies to Fetal Calf Serum With Arthus-Like Reactions in Human Immunodeficiency Virus–Infected Patients Given Syngeneic Lymphocyte Infusions. Blood, 1997, 89, 776-779.	1.4	254
46	Comparative analysis of whole blood lysis methods for flow cytometry. , 1997, 30, 124-133.		85
47	Comparative analysis of whole blood lysis methods for flow cytometry. Cytometry, 1997, 30, 124-133.	1.8	2
48	Measurement of T-cell CD69 expression: A rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. , 1996, 26, 305-310.		93
49	Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with wegener's granulomatosis. Arthritis and Rheumatism, 1993, 36, 365-371.	6.7	271
50	A 20 Year Clinical and Laboratory Study of Familial B-Chronic Lymphocytic Leukemia in a Single Kindred. Leukemia and Lymphoma, 1991, 3, 331-342.	1.3	13
51	Two-Color flow cytometric analysis of monocyte depleted human blood lymphocyte subsets. Cytometry, 1988, 9, 309-315.	1.8	25